Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Non-Current Assets (2018 - 2025)

Bicycle Therapeutics' Non-Current Assets history spans 8 years, with the latest figure at $21.9 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 27.45% year-over-year to $21.9 million; the TTM value through Dec 2025 reached $21.9 million, up 27.45%, while the annual FY2025 figure was $21.9 million, 27.45% up from the prior year.
  • Non-Current Assets reached $21.9 million in Q4 2025 per BCYC's latest filing, up from $11.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $37.0 million in Q1 2023 to a low of $5.7 million in Q3 2021.
  • Average Non-Current Assets over 5 years is $21.6 million, with a median of $22.2 million recorded in 2024.
  • Peak YoY movement for Non-Current Assets: skyrocketed 442.27% in 2022, then crashed 44.58% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $17.8 million in 2021, then surged by 84.2% to $32.8 million in 2022, then fell by 15.52% to $27.7 million in 2023, then tumbled by 37.91% to $17.2 million in 2024, then grew by 27.45% to $21.9 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Non-Current Assets are $21.9 million (Q4 2025), $11.4 million (Q3 2025), and $14.1 million (Q2 2025).